Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05308901
Title Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naive Metastatic Uveal Melanoma
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Providence Health & Services

uveal melanoma


Lenvatinib + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.